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Background: Ticagrelor reduced cardiovascular events and mortality compared to clopidogrel in the PLATO (PLATelet inhibition and patient 
Outcomes) trial. The use of a glycoprotein IIb/IIIa inhibitor (GPI) is recommended in high-risk patients undergoing percutaneous coronary 
intervention (PCI) for acute coronary syndromes (ACS). We evaluated the efficacy and safety of ticagrelor and clopidogrel with or without GPI use in 
such patients.
methods: The PLATO trial randomized 18,624 patients with ACS to ticagrelor or clopidogrel, with GPI use per physician discretion. We examined the 
subgroup of 10,429 patients who underwent PCI within 72 hours. We examined efficacy and safety endpoints at 30 days stratified by GPI use.
results: A total of 3858 patients (37%) received a GPI during their index hospitalization. Those receiving a GPI were more often younger (59 vs 61 
yrs), male (80% vs. 75%), smokers (44% vs. 42%) and underwent multi-vessel PCI (14.6% vs. 12.5%). There was no interaction between treatment 
and GPI use for the efficacy endpoints (p interaction=0.35 for primary composite outcome). There was also no significant interaction for the safety 
endpoint of PLATO major bleeding (p interaction= 0.12, Fig. 1).
conclusions: The effect of ticagrelor compared to clopidogrel on vascular death, myocardial infarction or stroke and PLATO major bleeding was 
consistent, with or without GPI use, in patients with ACS who underwent PCI.
